Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IARS1 | P41252 | 6/20 | 0.41 |
| ▸ | DPP4 | P27487 | 10/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23408814 | 1.00 | IARS1 (0.41) | IARS1DPP4DPP8DPP9CA12 | |
| SCHEMBL196042 | 0.84 | IARS1 (0.43) | IARS1DPP4DPP8DPP9DPP7 | |
| SCHEMBL19366508 | 0.84 | IARS1 (0.43) | IARS1DPP4DPP8DPP9DPP7 | |
| SCHEMBL196043 | 0.84 | IARS1 (0.43) | IARS1DPP4DPP8DPP9DPP7 | |
| SCHEMBL10514022 | 0.84 | SLC1A2 (0.43) | IARS1 | |
| Hydrochloric Acid SCHEMBL10437071 | 0.82 | IARS1 (0.42) | IARS1DPP4DPP8DPP9DPP7 | |
| SCHEMBL22392169 | 0.82 | IARS1 (0.38) | IARS1DPP4DPP8DPP9DPP7 | |
| SCHEMBL19361329 | 0.82 | CA12 (0.42) | DPP4CA12CA1CA2CA9 | |
| SCHEMBL25039128 | 0.82 | CA12 (0.42) | DPP4CA12CA1CA2CA9 | |
| SCHEMBL7366588 | 0.81 | ALDH1A1 (0.47) | IARS1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905683-B2 | Compositions and uses of amidine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905683-B2 | Compositions and uses of amidine derivatives | HRH3, HRH2, HRH1 | IARS1 2264/4885DPP4 4123/4885DPP8 3849/4885 |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | HRH3, HRH2, HRH1 | IARS1 2264/4885DPP4 4123/4885DPP8 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.